This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Recurrent miscarriage: diabetes drug could ... An existing drug can be used to improve the womb for pregnancy, ... (08 Jan 2020)
Nerve Stimulation May Benefit Women with ... A treatment involving electrical nerve stimulation helped women ... (08 Jan 2020)
Cancer drugs could potentially treat COPD, ... New research from the University of Sheffield shows a certain ... (08 Jan 2020)
Tea drinkers live longer Drinking tea at least three times a week is linked with a longer ... (08 Jan 2020)
How diet affects mental health – what’s the ... A new expert review confirms that diet significantly influences ... (08 Jan 2020)
×

Warning

JUser: :_load: Unable to load user with ID: 5232
Wednesday, 23 October 2019 21:03

Can polyunsaturated fatty acids provide treatment for depression? Featured

Rate this item
(0 votes)

An investigation in the current issue of Psychotherapy and Psychosomatics provides some new data on the potential application of some natural substances in depression.

An investigation in the current issue of Psychotherapy and Psychosomatics provides some new data on the potential application of some natural substances in depression. Endocannabinoids (ECs) are one type of bioactive endogenous neuroinflammatory mediator derived from polyunsaturated fatty acids, which may regulate the emotional processes. This study assessed the effect of ω–3 polyunsaturated fatty acids on endocannabinoid levels, which may be the novel targets for the ω–3 polyunsaturated fatty acids'antidepressive effects.

In a 12-week double-blind, nonplacebo, randomized controlled trial, 88 major depressive disorder (MDD) participants were randomly assigned to receive eicosapentaenoic acid (EPA, 3.0 g/day), docosahexaenoic acid (DHA, 1.4 g/day), or a combination of EPA (1.5 g/d) and DHA (0.7 g/day). Eighty-five participants completed the trial, and their clinical remission and plasma polyunsaturated fatty acids-derived endocannabinoidlevels (pmol/mL) were measured.

Results showed that the cumulative rates of clinical remission were significantly higher in the EPA and EPA + DHA groups than the DHA group.EPA and EPA + DHA treatments increased the eicosapentaenoyl-ethanolamide (EPEA) levels compared to DHA treatment, while EPA + DHA treatment increased the docosahexaenoyl-ethanolamide levels more than EPA treatment. More important, plasma EPEA levels were positively correlated with rates of clinical remission.

These findings showed that treatments enriched with EPA increased plasma EPEA levels, which, in turn, was positively associated with clinical remission. The Authors concluded thatlevels of plasma EPEA play a potential novel endogenous therapeutic target in MDD.


Source: Journal of Psychotherapy and Psychosomatics

Full bibliographic information

Clinical Efficacy and Biological Regulations of ω–3 PUFA-Derived Endocannabinoids in Major Depressive Disorder. Psychother Psychosom 2019;88:215–224
https://www.karger.com/Article/FullText/501158

Read 292 times Last modified on Thursday, 24 October 2019 11:57

Latest news

Highlights

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…